Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Azathioprine; Cyclophosphamide; Methylprednisolone; Mycophenolate; Steroids
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms BLISS-LN
- Sponsors GlaxoSmithKline; GSK; Human Genome Sciences
- 18 Jul 2023 Results of post hoc analysis, assess belimumab efficacy on kidney-related outcomes in newly diagnosed and relapsed LN subgroups, and according to use of glucocorticoid pulses at induction, published in the Nephrology Dialysis Transplantation
- 01 Mar 2023 Results of prespecified subgroup analysis (n=142) assessing the efficacy and safety of belimumab in the BLISS-LN East Asian subgroup, published in the American Journal of Kidney Diseases.
- 01 Nov 2022 Results(n=255 of Open-Label Extension of BLISS-LN Study) assessing Safety and Efficacy of Belimumab in Patients with Lupus Nephritis published in the Clinical Journal of The American Society of Nephrology: CJASN